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ABSTRACT. CXCR4 is the chemokine receptor which aids in chemo-
taxis of stem cells, such as those in the bone marrow or the brain. SDF-1 
is the natural ligand for the CXCR4 receptor. Similarities between novel 
molecule 390 synthesized by the Miller Lab and SDF-1 make this novel 
small molecule a possible agonist of the CXCR4 receptor. To determine 
whether 390 is an agonist to the CXCR4 receptor, we transfected cells 
with CXCR4 and exposed them to no agonist [vehicle control], SDF-1, or 
varying concentrations of our agonist drug. Next, we took calcium images 
using the dye fura-2, which indicates changes in calcium concentration in 
the cell due to CXCR4 activation. There was an increase in calcium in the 
cells when 390 was added, indicating that the receptor was being activated. 
When compared to the natural ligand, SDF-1, the levels were not as high, 
but they were higher than with the vehicle control. In the internalization as-
say, both SDF-1 and 390 internalized the receptor. The results suggest 390 
is an agonist or partial agonist of the CXCR4 receptor. 390 may be the first 
small molecule agonist of CXCR4 receptors ever identified and may have a 
number of uses in medicine.
INTRODUCTION. 
CXCR4 is a chemokine receptor, and is found on a variety cells, including 
cancerous and stem cells [1]. Chemokines are small signaling proteins, or cy-
tokines, that are released by the cell to induce chemotaxis, or cell movement, 
in nearby cells. For example, in the immune response, damaged tissue releases 
chemokines that induce chemotaxis of white blood cells to the area of injury. 
As a CXC-type chemokine receptor, or a receptor that responds to CXC che-
mokines, CXCR4 aids in cell chemotaxis when it is stimulated by chemokines 
[2]. The chemotactic function of CXCR4 is demonstrated in the receptor’s 
role of anchoring hematopoietic stem cells in the bone marrow [3]. Once it 
is activated by its natural ligand and chemokine, Stromal Cell Derived Factor 
1 (SDF-1/CXCL12), the CXCR4 ligand stimulates the stem cells to undergo 
chemotaxis [4]. While an agonist activates a receptor, an anatagonist prevents 
agonist-mediated stimulation of a receptor. Since these stem cells can be moved 
in the body through agonist interaction with CXCR4, discovering a small mol-
ecule receptor stimulant can potentially facilitate organ or tissue transplants 
[5]. Conversely, CXCR4 antagonists may be used to block the metastasis, or 
spread, of cancer cells by preventing them from moving into other parts of the 
body. Many types of cancer cells express the CXCR4 receptor and studies have 
shown that interference with the activation of the receptor by SDF- inhibited 
the spread of the cancer cells [3]. This receptor is also used by the HIV-1 virus 
to infect human body cells [6]. Finding an antagonist of the receptor could pre-
vent the entry of HIV-1 into cells and, in turn, the spread of the virus; however, 
the usage of an agonist could still benefit treatment of HIV [7]. As mentioned 
earlier, CXCR4 agonists may be crucial in stem cell chemotaxis.
390 is a novel small organic molecule synthesized by the Miller Lab at 
Northwestern University, which we have now demonstrated may act on 
the CXCR4 receptor as an agonist. We thought it might be an agonist for 
CXCR4 because the structure was similar to prior known agonists of CXCR4. 
Previously, the only molecules that have been made to activate CXCR4 are large 
peptides; this means that 390 may be a more appealing drug candidate than 
other CXCR4 agonists. While other similar compounds are peptide based and 
have large molecular weights, molecule 390 is small and compact. This suggests 
that 390 may be both easier and cheaper to produce than other CXCR4 ago-
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nist compounds, although peptide alternatives mass-produced in E.coli may be 
cheaper to produce. 
During this experiment, we conducted two assays: a calcium imaging assay and a 
receptor internalization assay. These two experiments were chosen to target two 
of the characteristics of CXCR4 agonists. The calcium imaging assay was chosen 
because CXCR4 agonists, such as SDF-1, are known to signal via G proteins in 
the cell, which result in increased cellular calcium levels when the receptor is ac-
tivated [8]. Hence, increased calcium levels can indicate activation of CXCR4 by 
an agonist. Also, internalization of the CXCR4 can occur when the receptor is 
overstimulated or desensitized i.e., during CXCR4 agonist stimulation on CXCR4 
expressing cells [9]. Therefore, an increase in calcium as well as internalization of 
CXCR4 was used to confirm that drug 390 was an agonist of the receptor.
MATERIALS AND METHODS. 
Cell Passage.
Cell passage using C8161 melanoma cells (passage 17-21) that already have 
CXCR4 expressed in them were used in the Calcium Imaging Assay. Human 
Embryonic Kidney 293 cells (HEK 293-passage 71) were used in the internaliza-
tion assay. Standard Practices for trypsinization and cell culture were done, using 
Life Technologies DMEM, DMEM + 10% FBS + Pen/Strep, and poly-L-lysine. 
Calcium Imaging Assay.
In the calcium imaging assay, after the cell passage of the C8161 melanoma 
cells, fura-2 and calcium buffer were added. An Olympus IX71calcium imag-
ing machine was used. A line willed with calcium buffer was set up, providing 
the ability to add either drug 390 or SDF-1 to cells and wash it off afterwards, 
while recording the change in the calcium levels. Then, one of the coverslips 
was taken and placed on the stage of the confocal microscope attached to the 
calcium imaging machine. Calcium buffer warmed to 37˚C was applied on top 
of the coverslip and then put it in the machine. Compound 390 or SDF-1 was 
then added at appropriate concentrations (10 μM, 1 μM, 0.1 μM, and 0.01 μM); 
once the observation of the change in calcium levels occurred, the cells were 
washed and we added four concentrations four concentrations (10 μM, 1 μM, 
0.1 μM, and 0.01 μM) of Molecule 390 or AMD 3100, a known antagonist of 
CXCR4 [10]. Data from this assay were recorded and saved using MetaFluor 
Fluorescence Ratio Imaging Software. This data was averaged and graphed with 
Microsoft Excel. The experiment was conducted eight times.
Receptor Internalization Assay.
For the receptor internalization assay, after passaging the HEK 293 cells, they 
were transfected with cDNA for CXCR4-YFP. This version of CXCR4 has a 
yellow fluorescent tag attached to it. The cells were transfected by aspirating 
old media from cells and replacing it with DMEM + 10% FBS. This was done 
on cells that were 80-90% confluent. The cells were allowed to equilibrate for 
one to one and a half hours. Then in six different tubes, DMEM and CXCR4-
YFP were mixed. These tubes were allowed to incubate for five minutes and 
then a Lipofectamine and DMEM mixture (8:1000) were added to the tubes. 
Afterwards, each tube was triturated for twenty to thirty seconds and incubat-
ed for twenty minutes with the caps open. Afterwards, we added the complex 
to cells and incubated for 48 hours. Then, four concentrations of drug 390 or 
SDF-1 were added to one well each, leaving one well for the negative control. 
These cells were incubated for two hours before taking the images of the cells. 
A confocal microscope was then used image the cells at 10x and 60x. DAPI was 
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DISCUSSION.
Both the calcium imaging and receptor internalization assays that were con-
ducted resulted in a promising future for small molecule drug 390 as an ago-
nist at CXCR4 receptors. First of all, in the calcium images, an increase in the 
amount of calcium ions after the application of SDF-1 to the C8161 cells was 
observed (Figure 1). Since this increase in calcium ions is indicative of CXCR4 
activation, this result was expected because SDF-1 is the natural ligand to 
CXCR4. After 390 was applied to the CXCR4 receptor at both 70 and 690 sec-
onds, the concentration of calcium in the cell increased (Figure 2). In addition, 
drug 390 was applied to the cells in the presence of AMD 3100. AMD 3100 is a 
known antagonist, or inhibitor, of the CXCR4 receptor. Because it binds to the 
receptor and prevents anything else from stimulating it, calcium ion levels were 
expected to be unaffected in the presence of both AMD 3100 and 390. This 
hypothesis was confirmed by the result in Figure 2 during the time of AMD 
3100 application, from 320 to 620 seconds. This confirmed that the increases 
in calcium that were seen after the application of 390 occurred as a result of the 
drug’s agonist properties instead of as a byproduct of an outside process.
The results of the internalization assay are summarized by Figure 2. In the con-
trol trial, use of a confocal microscope allowed us to determine high levels of 
CXCR4 receptors on the periphery associated the cell membranes of the trans-
fected HEK 293 cells. An image taken by a confocal microscope shows that, in 
the control trial, the majority of the CXCR4 receptor, labeled in yellow, was 
on the periphery of the cell. Unlike the control, SDF-1 application resulted in 
higher concentrations of CXCR4 on the inside of the cells. This indicates that 
the CXCR4 was internalized in the presence of SDF-1 as a result of desensi-
tization and overstimulation of the receptor. After the addition of 10 μM of 
drug 390, high levels of CXCR4 internalization were also observed (Fig. 2). 
This quantified data is visible in Figure 3, where numerous CXCR4 expressing 
cells exhibit high concentrations of CXCR4 inside of their cell membranes in 
vesicles in the cell cytoplasm. Similarly, the application of 1 μM of molecule 390 
led to high levels of CXCR4 internalization (Fig. 2). Images of the 1 μM trial 
used to stain the nucleus of the cells to differentiate between each cell after tak-
ing the images. After the images were taken, the program, “Fiji is just ImageJ,” 
was utilized in order to quantify the data from the images. Regions of interests 
were then drawn around the cells and their periphery to obtain the integrated 
density of CXCR4 measured either internalized into the cell or expressed in 
the cell membrane. Next, the percentages of CXCR4 internalized and on the 
membrane of the cells were calculated using Microsoft Excel. This assay was 
conducted five times.
RESULTS.
Calcium Imaging Assay.
Life Technologies Fura-2 is a fluorescent dye that binds to calcium ions and 
emits a specific fluorescent signal in order to see the increase in the cellular cal-
cium concentration when the experiment was performed. The calcium imag-
ing assay reports a fluorescent ratio which is related to the intracellular calcium 
concentration using the average of 20 cells. From a baseline ratio of around 50% 
calcium, the calcium ratio increased to 60% (Fig. 1) following addition of SDF-
1. In the second run of the calcium imaging assay (Fig. 1), there was a baseline 
of about 40% calcium . After the first application of 390, the Calcium levels 
increased to around about 70%. When AMD 3100 was applied and then 390, 
there was no increase in Calcium, clearly demonstrating that the agonist like 
effect of 390 was blocked by a well validated CXCR4 antagonist AMD 3100. 
Following washout of the AMD 3100 upon the third application of 390, the 
calcium levels increased from around 45% to around 75%, demonstrating that 
the block by AMD 3100 was reversible.
Receptor Internalization Assay.
In the receptor internalization assay, using the averages of at least 20 cells per 
treatment, it was found that in the control, 69% of the CXCR4-YFP was associ-
ated with the cell membrane while, 31% was internalized into the cytoplasm 
(Fig. 2). Following treatment with SDF-1, 10 μM treatment, 1 μM, 0.1 μM 
treatment, and .01 μM treatment, the percentage of CXCR4 internalized in-
creased, while the percentage of CXCR4 in the cell membrane decreased (Fig. 
2). Thus 390 produced a dose dependent increase in the degree of CXCR4-YFP 
internalization. 
Figure 1. Top graph: Amount of calcium from CXCR4 transfected cells before and 
after application of SDF-1 at 30 seconds. Bottom graph: Average response of cells 
responding to application of small molecule 390 at 80 seconds, 525 seconds, and 
725 seconds, which is indicated by black arrows. Notice that there is no increase in 
calcium in the presence of AMD 3100 (blue line).
Figure 2. Average expression of CXCR4 in the periphery (dark blue) and internal 
(light blue) regions of the cell.
Figure 3. Receptor Internalization images of all treatments showing expression of 
CXCR4 (yellow) in C8161 melanoma cells with nuclei stained with DAPI. 
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Figure S2. The image on the right shows cells with a negative control at10X 
magnification. The image on the left shows cells with a negative control at 60X 
magnification.
Figure S3. The image on the right shows cells with SDF-1 at10X magnification. 
The image on the left shows cells with SDF-1 at 60X magnification.
Figure S4. The image on the right shows cells with 10 μM 390 at10X magnifica-
tion. The image on the left shows cells with 10 μM 390 at 60X magnification.
Figure S5. The image on the right shows cells with 1 μM 390 at10X magnifica-
tion. The image on the left shows cells with 1 μM 390 at 60X magnification.
Figure S6. The image on the right shows cells with 0.1 μM 390 at10X magnifi-
cation. The image on the left shows cells with 0.1 at 60X magnification.
Figure S7. The image on the right shows cells with 0.01 μM 390 at10X magnifi-
cation. The image on the left shows cells with 0.01 at 60X magnification.
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showed many CXCR4 expressing cells with high levels of yellow inside of the 
cell, indicating receptor internalization (Fig. 3). While the 0.1 μM and 0.01 μM 
concentrations of 390 showed some internalization of CXCR4, the 10 μM and 
1 μM trials produced images that were significantly more similar to the Figure 
2, which showed CXCR4 internalization after the application of CXCR4. This 
led to the conclusion that small molecule 390 is an agonist or partial agonist of 
the CXCR4 receptor and is the most effective in higher concentrations and is 
not effective in the presence of AMD3100.
CONCLUSION. 
In conclusion, novel small molecule 390 caused cell calcium ions concentration 
to increase in a dose dependent manner (Fig. 1). 390 also caused the internal-
ization of CXCR4 from the cell membrane to the cytoplasm (Fig. 2). 
FUTURE DIRECTIONS.
Although the results of the calcium imaging assay shows that 390 acts as an ago-
nist of CXCR4 receptors, the fact that it eventually causes the receptor to inter-
nalize into cells may mean that it acts as a de facto antagonist when used in vivo 
through overall desensitization of receptor signaling. This possible antagonist 
effect in vivo could have several uses. When it is activated, CXCR4 holds stem 
cells in the bone marrow, where they are made. Anything that inhibits SDF-1 
will allow for the removal of hematopoietic stem cells from the bone marrow 
and the use of these stem cells to help with organ transplants. In addition, the 
CXCR4 is used by HIV-1 to gain entry into cells. If the receptor is inhibited or 
internalized by a drug, the virus may be prevented from infecting the cell.
An interesting future study of CXCR4 involves monitoring the effects of the ag-
onist drug in vivo. Because certain compounds that are verified as agonist in the 
lab setting have been shown to be antagonists in the body because they cause 
receptor internalization, seeing the effects of our small molecule agonist is used 
in vivo could affect in which situations 390 is administered.
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SUPPORTING INFORMATION. 
Supplemental Methods.
Figure S1. The image on the left is SDF-1, the natural ligand of CXCR4. On the 
right is the chemical structure of Molecule 390. The molecular weights of both 
compounds are included in the image.
